




AMENDMENTS TO THE CLAIMS

Please cancel claims 16-26 without prejudice.

1. (Currently amended) A fluorogenic composition for the detection of the activity of a protease, said composition having the formula:



wherein, P has the sequence is a peptide selected from the group consisting of ~~DEVVDGIN (SEQ ID NO:196), (d-O)DEVVDGIN (SEQ ID NO:197), DEVGDID (SEQ ID NO:198), LVEIDNG (SEQ ID NO:199), GIETESGV (SEQ ID NO:200), TGRT (SEQ ID NO:201), VMTGRT (SEQ ID NO:202), SEVKLDAEF (SEQ ID NO:203), S(d-E)VK(d-L)DAE(d-F) (SEQ ID NO:204), EDVVCCS (SEQ ID NO:205), EEVEGIN (SEQ ID NO:206), D(d-F)VDGIN (SEQ ID NO:207), (d-D)EV(d-D)GIN (SEQ ID NO:208), LVEIENG (SEQ ID NO:209), GIETDSG (SEQ ID NO:210), GIETESG (SEQ ID NO:211), LEHDGIN Leu-Glu-His-Asp-Gly-Ile-Nlu (SEQ ID NO:212), LETDGIN (SEQ ID NO:213), WEHDGIN (SEQ ID NO:214), YVHDG (SEQ ID NO:215), YVHDGIN (SEQ ID NO:216), YVHDA (SEQ ID NO:217), TGRTG (SEQ ID NO:218), S(d-E)VK(d-L)DAE(d-F) (SEQ ID NO:219), IEPDS (SEQ ID NO:220), PLGIAGI (SEQ ID NO:221), SQNYPIVQ (SEQ ID NO:222);~~

F¹ and F² are fluorophores and F¹ is attached to the amino terminal amino acid and F² is attached to the carboxyl terminal amino acid;

S¹ and S², when present, are peptide spacers ranging in length from 1 to about 50 amino acids and S¹, when present, is attached to the amino terminal amino acid and S², when present, is attached to the carboxyl terminal amino acid;

i, j, k, l, m, n, o, p, q, and r are independently 0 or 1;

aa¹ and aa¹⁰ are independently selected from the group consisting of lysine, ornithine and cysteine;

DS
W.M.H.

aa², aa³, aa⁸, and aa⁹ are independently selected from the group consisting of ~~an amino acid or a dipeptide consisting of~~ Asp, Glu, Lys, Ornithine, Arg, Citulline, homocitrulline, Ser, homoserine, Thr, and Tyr;

aa⁵, aa⁴, aa⁶, and aa⁷ are independently selected from the group consisting of proline, 3,4-dehydroproline, hydroxyproline, alpha aminoisobutyric acid and N-methyl alanine;

X is selected from the group consisting of Gly, β Ala, γ Abu, Gly-Gly, Ahx, C7, β Ala-Gly, β Ala- β Ala, γ Abu-Gly, β Ala- γ Abu, Gly-Gly-Gly, γ Abu- γ Abu, Ahx-Gly, β Ala-Gly-Gly, Ahx- β Ala, β Ala- β Ala-Gly, Gly-Gly-Gly-Gly (SEQ ID NO:223), Ahx- γ Abu, β Ala- β Ala- β Ala, γ Abu- β Ala-Gly, γ Abu- γ Abu-Gly, Ahx-Ahx, γ Abu- γ Abu- β Ala, and Ahx-Ahx-Gly;

Y is selected from the group consisting of Gly, β Ala, γ Abu, Gly-Gly, Ahx, C7, Gly- β Ala, β Ala- β Ala, Gly- γ Abu, γ Abu- β Ala, Gly-Gly-Gly, γ Abu- γ Abu, Gly-Ahx, Gly-Gly- β Ala, β Ala-Ahx, Gly- β Ala- β Ala, Gly-Gly-Gly-Gly, γ Abu-Ahx, β Ala- β Ala- β Ala, Gly- β Ala- γ Abu, Gly- γ Abu- γ Abu, Ahx-Ahx, β Ala- γ Abu- γ Abu, and Gly-Ahx-Ahx;

when i is 1, S¹ is joined to aa¹ by a peptide bond through a terminal alpha amino group of aa¹; and when r is 1, S² is joined to aa¹⁰ by a peptide bond through a terminal alpha carboxyl group of aa¹⁰.

2. (Original) The composition of claim 1, wherein the carboxyl terminal amino acid in which the carboxylic acid group is replaced with an amide.

3. (Original) The composition of claim 1, wherein

r is zero; and

aa¹⁰ has a C-terminal amide group or free carboxylic acid group.

4. (Currently amended) The composition of claim 1, having ~~the~~ ~~an~~ amino acid sequence selected from the group consisting of ~~Fm KDPJGDEVDGINGJPKGY (SEQ ID NO:224), Fm KDPJGDEVDGINGJPKamide (SEQ ID NO:225), Fm KDPJG(d-O)DEVDGINGJPKGY (SEQ ID NO:226), Fm KDPJGDEVDGINGPKGY (SEQ ID NO:227), Fm KDPGDEVDGINGJPKGY (SEQ ID NO:228), Fm KDPJGDEVDGIDGJPKamide (SEQ ID NO:229), Fm KDPJGLVEIDNGJPKGY (SEQ ID NO:230), Fm KDPJGIETESGVGJPKGY (SEQ ID NO:231), Fm KDPJTGRTPKGY (SEQ ID NO:232), Fm DPTGRTGPKGY (SEQ ID NO:233), Fm~~

D14 Anchored

~~KDPVMTGRTGJPKGY (SEQ ID NO:234), Fm KDPGTGRTGJPKGY (SEQ ID NO:235), Fm-~~
~~KDPJGTGRTGJPKGY (SEQ ID NO:236), Fm KDPJGTGRTGPKGY (SEQ ID NO:237), Fm-~~
~~KDPGTGRTGPKGY (SEQ ID NO:238), Fm KDPJGSEVKLDAEFGJPKGY (SEQ ID NO:239), Fm-~~
~~KDPJGS (d E)VK (d L)DAE (d F) GCSPKDDY (SEQ ID NO:240), Fa-~~
~~KDPJGEDVVCCSGJPKGY (SEQ ID NO:241), KDPJGEVEVINGJPKGY (SEQ ID NO:242),~~
~~KDPJGD (d F)VDGINGJPKGY (SEQ ID NO:243), KDPJG (d D)EV (d D)GINGJPKGY (SEQ ID~~
~~NO:244), KDPJGLVEIENGJPKGY (SEQ ID NO:234), KDPJGIETDSGJPKGY (SEQ ID NO:246),~~
~~KDPJGIETESGJPKGY (SEQ ID NO:247), KDPJGLEHDGINGJPKGY Lys-Asp-Pro-Ahx-Gly-Leu-~~
~~Glu-His-Asp-Gly-Ile-Nlu-Gly-Ahx-Pro-Lys-Gly-Tyr (SEQ ID NO:248), KDPJGLETDGINGJPKGY~~
~~(SEQ ID NO:249), KDPJGWHDGINGJPKGY (SEQ ID NO:250), KDPJGYVHDGJPKGY (SEQ ID~~
~~NO:251), KDPJGYVHDGINGJPKGY (SEQ ID NO:252), KDPJGYVHDAPKGY (SEQ ID NO:253),~~
~~KDPJTGRTGJPKGY (SEQ ID NO:254), KDPC3TGRTPKGY (SEQ ID NO:255),~~
~~KDPC7TGRTPKGY (SEQ ID NO:256), KDPC5GS(d E)VK(d L)DAE(d F)GJPKGY (SEQ ID~~
~~NO:257), KDPJGIEPDSGJPKGY (SEQ ID NO:258), KDPJGPLGIAGIGJPKGY (SEQ ID NO:259),~~
~~and KDPJGSQNYPIVQGJPKGY (SEQ ID NO:260).~~

5. (Original) The composition of claim 1, wherein F¹ and F² are the same fluorophore.

D17

6. (Currently Amended) The composition of claim 5, wherein said F¹ and F² have an excitation wavelength ~~between about in the range of 315 nm and about to~~ 700 nm.

7. (Original) The composition of claim 1, wherein the F¹ molecule is attached through either an α-amino group of the aa¹ amino acid or through a side chain amino group of the aa¹ amino acid, or through a sulphydryl group of a side chain of the aa¹ amino acid.

8. (Original) The composition of claim 1, wherein the F² molecule is attached either through a side chain amino group of the aa¹⁰ amino acid, through a carboxyl group of the aa¹⁰ amino acid, or through a sulphydryl group of a side chain of the aa¹⁰ amino acid.

9. (Original) The composition of claim 1, wherein said fluorophore is selected from the group consisting of rhodamine X, 9-(2,5 (or 2,6)-dicarboxyphenyl)-3,6-bis(dimethylamino)xanthylumhalide or other anion (TMR), 9-(2,5)-dicarboxyphenyl)-2,7-dimethyl-

3,6-bis(ethylamino)xanthylium halide or other anion (Rh6G), 9-(2,6)-dicarboxyphenyl)-2,7-dimethyl-3,6-bis(ethylamino)xanthylium halide or other anion, 9-(2,5 (or 2,6)-dicarboxyphenyl)-3,6-bisaminoxanthylium halide or other anion (Rh110), 9-(2,5 (or 2,6)-dicarboxyphenyl)-3-amino-6-hydroxyxanthylium halide or other anion (Blue Rh), carboxytetramethylrhodamine, carboxyrhodamine-X , diethylaminocoumarin, 9-(2,5-dicarboxyphenyl)-3,6-bis-(dimethylamino)xanthylium chloride (5-TMR), 9-(2,6-dicarboxyphenyl)-3,6-bis-(dimethylamino)xanthylium chloride (6-TMR), 9-(2-carboxyphenyl)-3,6-bis(dimethylamino)xanthylium, and 9-(2-carboxyphenyl)-xanthylium.

10. (Original) The composition of claim 1, wherein said composition bears a hydrophobic group.

11. (Original) The composition of claim 4, wherein said composition bears a hydrophobic group.

12. (Original) The composition of claim 11, wherein said hydrophobic group is selected from the group consisting of: Fmoc, 9-fluoreneacetyl group, 1-fluorenecarboxylic group, 9-florenecarboxylic group, and 9-fluorenone-1-carboxylic group, benzyloxycarbonyl, Xanthy (Xan), Trityl (Trt), 4-methyltrityl (Mtt), 4-methoxytrityl (Mmt), 4-methoxy-2,3,6-trimethyl-benzenesulphonyl (Mtr), Mesitylene-2-sulphonyl (Mts), 4,4-dimethoxybenzhydryl (Mbh), Tosyl (Tos), 2,2,5,7,8-pentamethyl chroman-6-sulphonyl (Pmc), 4-methylbenzyl (MeBzl), 4-methoxybenzyl (MeOBzl), Benzyloxy (BzlO), Benzyl (Bzl), Benzoyl (Bz), 3-nitro-2-pyridinesulphenyl (Npys), 1-(4,4-dimentyl-2,6-diaxocyclohexylidene)ethyl (Dde), 2,6-dichlorobenzyl (2,6-DiCl-Bzl), 2-chlorobenzyloxycarbonyl (2-Cl-Z), 2-bromobenzyloxycarbonyl (2-Br-Z), Benzyloxymethyl (Bom), t-butoxycarbonyl (Boc), cyclohexyloxy (cHxO), t-butoxymethyl (Bum), t-butoxy (tBuO), t-Butyl (tBu), Acetyl (Ac), and Trifluoroacetyl (TFA).

13. (Original) The composition of claim 12, wherein said hydrophobic group is Fmoc.

14. (Original) The composition of claim 12, wherein said hydrophobic group is Fa.

15. (Original) The composition of claim 12, wherein said hydrophobic group is attached to the amino terminus of the molecule.